I'm LongbridgeAI, I can summarize articles.Windtree Therapeutics sold its cardiovascular drug candidates to Seismic Pharmaceutical Operations via an asset purchase agreement. Windtree retains a 20% share of future proceeds and will receive $700,000 if Seismic secures at least $10 million in financing. Development payables transfer to Seismic, allowing Windtree to monetize assets and shift risk.
Windtree Therapeutics entered into an Asset Purchase Agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Operations. Windtree will receive 20% of any future proceeds generated by Seismic, including potential global commercial net revenue in acute heart failure if approved. Windtree will also receive $700,000 if Seismic completes a financing of at least $10 million to fund development. As part of the deal, certain development payables related to the cardiovascular candidates will transfer to Seismic.
Agreement details:
- Agreement type: Asset purchase agreement for cardiovascular drug candidates
- Counterparty: Seismic Pharmaceutical Operations
- Signed / Effective: Dec 16 2025 / same
- Duration / Termination: N/A
- Reason: Monetize assets and shift development risk and liabilities
Original SEC Filing: WINDTREE THERAPEUTICS INC /DE/ [ WINT ] - 8-K - Jul. 21, 2026